Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Status of a group B Neisseria meningitidis vaccine.

× No keyword cloud information.

24 in total

1. Immunologic response of man to group B meningococcal polysaccharide vaccines.

Authors: F A Wyle; M S Artenstein; B L Brandt; E C Tramont; D L Kasper; P L Altieri; S L Berman; J P Lowenthal
Journal: J Infect Dis Date: 1972-11 Impact factor: 5.226

2. Antigenic similarities between brain components and bacteria causing meningitis. Implications for vaccine development and pathogenesis.

Authors: J Finne; M Leinonen; P H Mäkelä
Journal: Lancet Date: 1983-08-13 Impact factor: 79.321

3. Clinical and serological evaluation of a meningococcal polysaccharide vaccine groups A, C, Y, and W135.

Authors: W A Hankins; J M Gwaltney; J O Hendley; J D Farquhar; J S Samuelson
Journal: Proc Soc Exp Biol Med Date: 1982-01

4. Safety and immunogenicity of a Neisseria meningitidis type 2 protein vaccine in animals and humans.

Authors: W D Zollinger; R E Mandrell; P Altieri; S Berman; J Lowenthal; M S Artenstein
Journal: J Infect Dis Date: 1978-06 Impact factor: 5.226

5. Monoclonal antibody that recognizes an outer membrane antigen common to the pathogenic Neisseria species but not to most nonpathogenic Neisseria species.

Authors: J G Cannon; W J Black; I Nachamkin; P W Stewart
Journal: Infect Immun Date: 1984-03 Impact factor: 3.441

6. Protection against group B meningococcal disease: evaluation of serotype 2 protein vaccines in a mouse bacteremia model.

Authors: D E Craven; C E Frasch
Journal: Infect Immun Date: 1979-10 Impact factor: 3.441

7. Development of a Neisseria meningitidis group B serotype 2b protein vaccine and evaluation in a mouse model.

Authors: L Y Wang; C E Frasch
Journal: Infect Immun Date: 1984-11 Impact factor: 3.441

8. Experimental meningococcal infection in neonatal mice: differences in virulence between strains isolated from human cases and carriers.

Authors: I E Salit; L Tomalty
Journal: Can J Microbiol Date: 1984-08 Impact factor: 2.419

9. Immunochemistry of groups A, B, and C meningococcal polysaccharide-tetanus toxoid conjugates.

Authors: H J Jennings; C Lugowski
Journal: J Immunol Date: 1981-09 Impact factor: 5.422

10. Protection against group B meningococcal disease. III. Immunogenicity of serotype 2 vaccines and specificity of protection in a guinea pig model.

Authors: C E Frasch; J D Robbins
Journal: J Exp Med Date: 1978-03-01 Impact factor: 14.307

11 in total

1. Specificity of human bactericidal antibodies against PorA P1.7,16 induced with a hexavalent meningococcal outer membrane vesicle vaccine.

Authors: E R van der Voort; P van der Ley; J van der Biezen; S George; O Tunnela; H van Dijken; B Kuipers; J Poolman
Journal: Infect Immun Date: 1996-07 Impact factor: 3.441

Review 2. Prospects for vaccine prevention of meningococcal infection.

Authors: Lee H Harrison
Journal: Clin Microbiol Rev Date: 2006-01 Impact factor: 26.132

3. Surface antigen analysis of group B Neisseria meningitis outer membrane by monoclonal antibodies: identification of bactericidal antibodies to class 5 protein.

Authors: M G Danelli; N M Batoreu; M D Lacerda; C R Ferreira; J D Cardoso; J M Peralta; C E Frasch
Journal: Curr Microbiol Date: 1995-09 Impact factor: 2.188

4. One Flu Over the Cuckoo's Nest.

Authors: H Seiden
Journal: Can Fam Physician Date: 1987-02 Impact factor: 3.275

5. Vol au-dessus d'un nid de coucous.

Authors: H Seiden
Journal: Can Fam Physician Date: 1987-03 Impact factor: 3.275

Review 6. Perspectives on the potential for successful development of outer membrane protein vaccines.

Authors: H E Gilleland; J M Matthews-Greer
Journal: Eur J Clin Microbiol Date: 1987-06 Impact factor: 3.267

7. Effectiveness of natural and synthetic complexes of porin and O polysaccharide as vaccines against Brucella abortus in mice.

Authors: A J Winter; G E Rowe; J R Duncan; M J Eis; J Widom; B Ganem; B Morein
Journal: Infect Immun Date: 1988-11 Impact factor: 3.441

Status of a group B Neisseria meningitidis vaccine.